Tocqueville Asset Management Takes 8.73% Stake in Inuvo
6:34 AM ET, 07/11/2014
In a 13D filing on Inuvo, Inc. (NYSE: INUV), hedge fund Tocqueville Asset Management disclosed a 8.73%, or 1,902,800 share, stake in the company. The firm did not hold shares at the end of the latest quarter ending March 31, 2014.
More from the 13D:
The Reporting Person acquired the Shares of the Issuer for investment purposes. The Reporting Person evaluates the investment in the Shares on a continual basis.
The Reporting Person has no plans or proposals as of the date of this filing which relate to, or would result in, any of the actions enumerated in Item 4 of the instructions to Schedule 13D.
Charles Morgan, who is an investor in a client of the Reporting Person, serves as a director of the Issuer.
Mylan is being honored for its charitable giving to WVU and commitment to enhance the areas and people it serves.
The West Virginia University Foundation has announced the recipients of its 2014 Outstanding Philanthropy awards.
Heather Bresch is chief executive officer of Mylan, one of the largest generics and specialty pharmaceutical companies in the world.
West Virginia University Provost Gerald Lang has resigned in the face of criticism over his handling of a master's degree improperly awarded to governor Joe Manchin’s daughter.
A panel appointed by WVU and featuring independent educators from New York, Missouri and Pennsylvania has been investigating how discrepancies about Ms. Bresch's degree were handled by school administrators in October. It has yet to release its conclusions.
The appointment of the panel was sparked by a Dec. 21 story by the Post-Gazette that raised questions about how the university awarded the degree to Ms. Bresch, despite records that showed she had completed only about half of the credits needed to earn the degree.
Ms. Bresch has repeatedly declined to comment to the Post-Gazette about questions surrounding her degree. She could not be reached for comment last night.
A buyout is always possible, but I was responding to the message posted mentioning that Zogenix will be acquired because the company cannot afford the cost of having Zohydro formulated into being tamper proof.
Please refrain from talking out of your rear end as the Altus Formulation cost is easily affordable:
Under the D&O Agreement, Altus has granted Zogenix an option (subject to the terms and conditions of the D&O Agreement) to enter into an exclusive license on mutually agreed terms to develop and commercialize abuse deterrent formulations of Zohydro ER in the United States. In connection with the transaction, Zogenix will pay Altus a technology access fee in the amount of $750,000. Zogenix will fund all development activities, and Altus may earn up to an additional $3.5 million in development and regulatory milestones through submission of a New Drug Application (NDA) under the D&O Agreement. Following exercise of the option, Altus will be eligible to receive additional undisclosed regulatory and sales milestone payments and a royalty based on net sales of the licensed product.
That would have to happen during the next 3 1/2 hours of trading tomorrow Thursday with the early close and that is highly doubtful with this Friday being a holiday unless you are talking about the following Friday and you will be broke and gone from this message board by that time if you are short.
There is nothing to discuss about any court ruling because there is not going to be a ruling, only an explanation reminding everyone that Federal Law trumps State Law. This is the United States of America, not the Ununited States of America. What unites the states is federal laws and powers for the good of all. A federal judge is bound by federal law to uphold the Constitution of the United States of America and not to start thinking that a judge is the Supreme Court. The Food and Drug Administration is more powerful than the Internal Revenue Service and no one who complains about a decision that was made by that agency is going to make an impact and reverse their processes which take companies years and years and millions of dollars to bring a product to market.
which is tomorrow.
If Duval speaks I sell rotten fruit and vegetables at a stand out in front and make a tidy profit.
of the proprietary formulations of the antibiotic ciprofloxacin (Pulmaquin and Lipoquin). These formulations are being developed for managing infections associated with severe respiratory diseases -- cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (:BE), and are administered through inhalation.
Pre Reverse Split adjusted this is only $2.50 a share and I estimate this value to be reasonable. It is a matter of success which will require waiting.
The Zogenix competitors have been put under the looking glass by politicians in California and the company is no longer being singled out, which is a huge relief. No progress will be made by lawmakers trying to blame all of the pharmaceutical companies, the Federal Government and the FDA for drug abuse. Other solutions will need to be addressed to educate the public through schools, communities and media awareness programs.